Literature DB >> 29885644

Treatment with acetyl-l-carnitine during in vitro maturation of buffalo oocytes improves oocyte quality and subsequent embryonic development.

Hui-Yan Xu1, Xiao-Gan Yang1, Sheng-Sheng Lu1, Xing-Wei Liang1, Yang-Qing Lu1, Ming Zhang1, Ke-Huan Lu2.   

Abstract

Oocyte quality is one of the important factors in female fertility, in vitro maturation (IVM), and subsequent embryonic development. In the present study, we assessed whether acetyl-l-carnitine (ALC) supplementation during in vitro maturation of buffalo oocytes could improve oocyte quality and subsequent embryonic development. To determine the optimal level of ALC supplementation, we matured cumulus-oocyte complexes in maturation medium supplemented with 0, 2.5, and 5 mM ALC. The oocytes with a polar body were selected for parthenogenetic activation (PA) and in vitro fertilization (IVF). We found that oocytes matured in 2.5 mM ALC had significantly higher PA blastocyst rate (P < 0.05) and blastocyst cell number than those of unsupplemented oocytes (P < 0.05) and a significantly higher IVF blastocyst rate than that of oocytes matured in 5 mM ALC (P < 0.05). In all further experiments, we supplemented the maturation medium with 2.5 mM ALC. We then tested whether ALC supplementation could improve various markers of oocytes and cumulus cells. We compared cell proliferation; concentrations of reactive oxygen species (ROS), intracellular ATP, estradiol, and progesterone; mitochondrial distribution; mitochondrial DNA copy number (mtDNA); and expression levels of four genes encoding oocyte-derived factors (GDF9, BMP15) and steroid hormones (StAR, P450scc) between the supplemented and unsupplemented oocytes and cumulus cells. Cumulus cells matured with ALC supplementation were more prolific than those matured without ALC supplementation (P < 0.05). Oocytes treated with ALC had lower concentrations of intracellular ROS (P < 0.05) and a higher rate of diffuse mitochondrial distributions (P < 0.05) than those of untreated oocytes. Additionally, the mtDNA was higher in the ALC-treated oocytes (P < 0.05) and cumulus cells (P < 0.05) than that in the untreated cells. The ALC-treated maturation medium had a higher postmaturation concentration of estradiol than that of the untreated medium (P < 0.05). Finally, the gene expression levels of P450scc and GDF9 were greater in ALC-treated oocytes and cumulus cells than those in untreated cells (P < 0.05). Therefore, in buffalo, our results suggest that ALC affects mitochondrial function, regulates oocyte-derived paracrine factors, and increases the production of steroid hormones, leading to increased quality of matured oocytes and improved embryonic development in vitro.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetyl-l-carnitine (ALC); Buffalo; Embryonic quality; IVM; Oocyte

Mesh:

Substances:

Year:  2018        PMID: 29885644     DOI: 10.1016/j.theriogenology.2018.05.033

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  4 in total

1.  Rosmarinic acid treatment during porcine oocyte maturation attenuates oxidative stress and improves subsequent embryo development in vitro.

Authors:  Yan Zhang; Jing Guo; Xiao Wei Nie; Zi Yue Li; Yu Meng Wang; Shuang Liang; Suo Li
Journal:  PeerJ       Date:  2019-06-18       Impact factor: 2.984

2.  Effects of Co-Administration of Bone Marrow Stromal Cells and L-Carnitine on The Recovery of Damaged Ovaries by Performing Chemotherapy Model in Rat.

Authors:  Sam Zarbakhsh; Robabeh Safari; Hamid Reza Sameni; Behpour Yousefi; Manouchehr Safari; Nasrin Khanmohammadi; Parisa Hayat
Journal:  Int J Fertil Steril       Date:  2019-07-14

3.  L-Carnitine Supports the In Vitro Growth of Buffalo Oocytes.

Authors:  Avijit Kumar Modak; Md Hasanur Alam; Md Nuronnabi Islam; Nipa Paul; Ireen Akter; Md Abul Hashem; Akm Ahsan Kabir; Mohammad Moniruzzaman
Journal:  Animals (Basel)       Date:  2022-08-02       Impact factor: 3.231

4.  The Mechanisms of Improving IVF Outcomes of Liu-Wei-Di-Huang Pill Acting on DOR Patients.

Authors:  Jimei Xiao; Jingyan Song; Yuanhong Sa; Lihua Yuan; Jiayin Guo; Zhengao Sun
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-31       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.